Notable healthcare headlines for the week: J&J, GSK, Merck, and Cassava Sciences in focus
Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...
Devdiscourse3d
Global Health and Pharmaceutical Updates: From Cyberattacks to Drug Approvals
The health sector faces challenges as Novo Nordisk's sales projections dim, Johnson & Johnson's unit faces hefty fines, and ...
Janssen Liability Increased to $1.6 Billion in Drug Fraud Suit
Janssen Products LP must pay over $1.6 billion in a False Claims Act suit for improperly billing the US government for HIV ...
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
(Reuters) -A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury ...
Healio5d
FDA recap: First new treatment for stroke in 3 decades, generic rivaroxaban and more
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Irish Examiner5d
Trump's tariff threat on Irish pharma sector puts €44bn exports at 'considerable risk'
Tariffs drive inflation, negatively impacting consumers on both sides of the Atlantic. Increased protectionism is in nobody’s ...
Pharmaceutical Technology5d
AGA overhauls UC treatment pathway: early, high-efficacy therapies now preferred
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...
Fentanyl: An explainer on the deadly opioid, Trump’s war and India's role
India with its vast pharmaceutical and chemical industries is an emerging source for fentanyl precursor chemicals. Mexican ...
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...